GANX
Gain Therapeutics, Inc.
Set alert
1.13 USD -0.06 -5.04%
1.11 Day range 1.20
1.13 52-week range 4.18
- YTD
- -64.91%
- 1 year
- -35.80%
- Open
- 1.18
- Prev close
- 1.19
- Mkt cap
- 49.32M
- Vol
- 364.65K
- Avg vol
- 501.79K
- EPS
- -0.50
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.11
- High
- 1.20
- Forward P/E
- -1.76
- Beta
- 0.34
- Short ratio
- 1.65
- Inst. own
- 7.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 2.05
- 200-d avg
- 2.12
- 1y target
- 7.33
Key statistics
- Market cap
- 41.64M
- Enterprise value
- 30.98M
- Trailing P/E
- 0.00
- Forward P/E
- -1.76
- PEG ratio
- 0.00
- Price / book
- 2.02
- EPS (TTM)
- -1.07
- Beta
- 0.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -10.06M
- Total cash
- 16.94M
- Total debt
- 807.57K
- Return on equity
- -188.83%
- Shares outstanding
- 26.53M
- Short % of float
- 2.71%
- 50-day average
- 2.05
- 200-day average
- 2.12
Analyst view
Consensus: none
Price target (mean) 7.33 +549.0% upside
Now 1.13
- Target (low)
- 5.00
- Target (mean)
- 7.33
- Target (high)
- 10.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy3
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.17333.
Financials — quick view
GANX Revenue — quarterly 0
GANX Net income — quarterly -4.68M
GANX EPS — quarterly -0.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.23 | -0.17 | +0.06 | +26.09% |
| Aug 8, 2024 | Jun 1, 2024 | -0.31 | -0.42 | -0.11 | -35.48% |
| Aug 8, 2024 | Jun 1, 2024 | -0.31 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.30 | -0.22 | +0.08 | +26.67% |
| May 14, 2024 | Mar 1, 2024 | -0.30 | — | — | — |
| Mar 26, 2024 | Dec 1, 2023 | -0.32 | -0.29 | +0.03 | +9.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Roth MKM | init | — | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 9, 2024 | Chardan Capital | main | Buy | Buy |
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gaintherapeutics.com
News
- Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to Clinic
- Gain Therapeutics to Attend the 2026 Maxim Growth Summit
- HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
- Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The 12 Evaluable Participants; Results Support Disease-Modifying Potential Of Rexaceract
- Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
- Gain Therapeutics Reveals Poster Presentation At International Congress Of Parkinson’s Disease and Movement Disorders
- Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders
- Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head Comparison
- Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
- HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
Your note
Sign in to keep a note on GANX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALDER MATTHIAS | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 25, 2024 | 21,140 |
| ISLAM KHALID | Officer and Director | Purchase | Aug 8, 2024 | 930,784 |
| MACK GENE C | Chief Executive Officer | Purchase | Aug 8, 2024 | 14,400 |
| RICHMAN ERIC I. | Director | Purchase | Jun 30, 2024 | 304,458 |
| RILEY JEFFREY SCOTT | Director | Purchase | Mar 27, 2024 | 30,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| DME Capital Management, LP | 2.13% | 566,130 | 888.82K | Sep 29, 2024 |
| Gotham Asset Management, LP | 1.26% | 334,592 | 525.31K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.03% | 271,972 | 427.00K | Sep 29, 2024 |
| Vanguard Group Inc | 0.55% | 145,217 | 227.99K | Sep 29, 2024 |
| Blackrock Inc. | 0.32% | 84,924 | 133.33K | Sep 29, 2024 |
| Jones Financial Companies, L.L.L.P. | 0.20% | 53,500 | 84.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.54% | 143,522 | 225.33K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.51% | 135,702 | 213.05K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.21% | 56,624 | 88.90K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 38,783 | 60.89K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 34,738 | 54.54K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 10,062 | 15.80K | Oct 30, 2024 |